相关实验视频

Updated: Jan 13, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

艾克西卡巴丁基洛洛塞尔与瑞图西马布联合用于耐火性大B细胞淋巴瘤:第二阶段,单臂ZUMA-14试验

Paolo Strati1, Lori Leslie2, Parveen Shiraz3

  • 1Department of Lymphoma and Myeloma and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pstrati@mdanderson.org.

Nature cancer
|January 6, 2026
PubMed
概括

将axicabtagene ciloleucel (axi-cel) 与rituximab相结合显示出大B细胞淋巴瘤 (LBCL) 的前景. 这种双重疗法实现了高的完全响应率和持久的结果,可能克服了CD19抗原逃逸.

更多相关视频

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K